Fluvastatin in the Therapy of Acute Coronary Syndrome

Novartis

Status and phase: Completed; Phase 4

Conditions: Myocardial Infarction; Coronary Disease

Treatments: Drug: Fluvastatin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00171275

CXUO320BCZ01

Details and patient eligibility

About

This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute coronary syndrome
• Adults, 18 years and older

Exclusion criteria

• History of lipid lowering therapy less than 30 days before index event
• Pregnancy and nursing
• Subject younger than 18 years

Other inclusion and exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind